Summit Wealth Group LLC Co. Purchases 37,996 Shares of Novo Nordisk A/S $NVO

Summit Wealth Group LLC Co. purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 37,996 shares of the company’s stock, valued at approximately $1,440,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Scarborough Advisors LLC bought a new position in Novo Nordisk A/S in the 1st quarter worth $26,000. Root Financial Partners LLC purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth about $32,000. Continuum Advisory LLC bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $38,000. Latitude Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at about $38,000. Finally, Markowski Investments bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $43,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Cfra cut shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price target on the stock. in a research report on Tuesday, September 22nd. Jefferies Financial Group restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. DZ Bank reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. BMO Capital Markets set a $40.00 price objective on Novo Nordisk A/S and gave the company a “market perform” rating in a research report on Monday, October 12th. Finally, Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Five analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $59.44.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo plans to repurchase 41.7 million shares under its $15 billion buyback program, which may support demand for the stock. Novo Nordisk stock and repurchases
• Positive Sentiment: New Wegovy and investigational CagriSema findings are expected at ObesityWeek, including real-world Wegovy results and additional CagriSema weight-loss outcomes. Strong data could bolster the obesity-drug pipeline and help restore confidence in future growth. Novo Nordisk obesity data
• Positive Sentiment: A valuation-focused article highlights NVO’s discount to sector peers, while another identifies the company as a potentially attractive dividend stock after a difficult year. These views may appeal to value-oriented investors, though they do not resolve near-term business risks. Novo Nordisk valuation Dividend-stock article
• Neutral Sentiment: Q3 results are a key upcoming catalyst. Investors are watching GLP-1 sales and management’s outlook; an article’s reference to substantial upside based on GF Value is a valuation estimate, not a forecast of earnings or share performance. Q3 results preview Earnings watch
• Negative Sentiment: Pre-earnings coverage flags intensifying GLP-1 competition, earnings estimate cuts and pricing pressure. Another report frames the November outlook around a trimmed target, while commentary points to a legal setback, Eli Lilly’s higher competitive bar and caveats around CagriSema. These concerns could weigh on growth expectations. Pre-earnings risks November challenges

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $40.14 on Wednesday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market cap of $179.23 billion, a P/E ratio of 9.81, a P/E/G ratio of 1.37 and a beta of 0.70. The business’s 50 day moving average price is $40.97 and its 200-day moving average price is $44.15. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. The company had revenue of $11.98 billion during the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.